Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
thiamine hydrochloride, Quantity: 50 mg/mL; riboflavine sodium phosphate, Quantity: 2.5 mg/mL; pyridoxine hydrochloride, Quantity: 5 mg/mL; dexpanthenol, Quantity: 2.5 mg/mL; nicotinamide, Quantity: 25 mg/mL; cyanocobalamin, Quantity: 0.5 mg/mL
Orthomolecular Medisearch Laboratories Pty Ltd Trading As Biological Therapies
Cyanocobalamin,Dexpanthenol,Nicotinamide,pyridoxine hydrochloride,riboflavine sodium phosphate,Thiamine hydrochloride
Injection, solution
Excipient Ingredients: water for injections
Intramuscular
1 x 10mL, 6 x 10mL
(S4) Prescription Only Medicine
This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code) B vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. Oral administration of B vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. Specific indications include: 1. Rapid saturation of the B group vitamins. 2. When oral administration is not feasible or appropriate. 3. For alcoholic, debilitated and elderly patients when their diet is inadequate. 4. Beriberi and Wernicke's syndrome as a result of Vitamin B1 deficiency. 5. Pellagra as a result of Vitamin B3 deficiency. Patients with pellagra may have a concurrent deficiency of B1, B2, B6 and B12. 6. Peripheral neuritis caused by various B group deficiencies. 7. Pernicious anaemia as a result of in
Visual Identification: Clear yellow/brown solution.; Container Type: Vial; Container Material: Glass Type I Coloured; Container Life Time: 1 Years; Container Temperature: Store at 2 to 8 degrees Celsius
Registered
1994-01-31